OST31-164 for Bone Cancer
(OST-164-01 Trial)
Trial Summary
What is the purpose of this trial?
This trial involves giving OST31-164 infusions to patients aged 12 to 39 with bone cancer that has returned in the lungs and been surgically removed. The treatment helps the immune system fight any leftover cancer cells. Patients will receive infusions periodically for several months and be monitored for a few years.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently on certain treatments like systemic antibiotics, corticosteroids, or chemotherapy. It's best to discuss your specific medications with the trial team.
How is the drug OST31-164 different from other treatments for bone cancer?
Research Team
Robert Petit, PhD
Principal Investigator
OS Therapies, Inc.
Eligibility Criteria
This trial is for 12 to 39-year-olds with osteosarcoma that has recurred in the lungs and was surgically removed. They must have had at least one lung recurrence, weigh over 40 kg, and not be pregnant or breastfeeding. Participants need a performance status of ECOG scores of 0-2 and should understand the study's risks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive OST31-164 infusions every 3 weeks for 48 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- OST31-164
Find a Clinic Near You
Who Is Running the Clinical Trial?
George Clinical Pty Ltd
Lead Sponsor